Cited by 1,248Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenomics and Rare Diseases

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The IARC TP53 database: New online mutation analysis and recommendations to users

Open access

Olivier, Magali, Eeles, Ros, Hollstein, Monica, Khan, Mohammed A., Harris, Curtis C., Hainaut, Pierre·2002·Human Mutation

DOI 10.1002/humu.10081

Open this paper in CoChat — free account Open PDF

Abstract

Mutations in the tumor suppressor gene TP53 are frequent in most human cancers. Comparison of the mutation patterns in different cancers may reveal clues on the natural history of the disease. Over the past 10 years, several databases of TP53 mutations have been developed. The most extensive of these databases is maintained and developed at the International Agency for Research on Cancer. The database compiles all mutations (somatic and inherited), as well as polymorphisms, that have been reported in the published literature since 1989. The IARC TP53 mutation dataset is the largest dataset available on the variations of any human gene. The database is available at www.iarc.fr/P53/. In this paper, we describe recent developments of the database. These developments include restructuring of the database, which is now patient-centered, with more detailed annotations on the patient (carcinogen exposure, virus infection, genetic background). In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/humu.10081

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M. L., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 899
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 180
p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 164
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 153
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 3

Greenblatt, 1994, Cancer Res, 54, 4855
Hollstein, 1994, Nucleic Acids Res, 22, 3551
Vahteristo, 2001, Cancer Res, 61, 5718

Sorted by citations

Items 901–1,000 of 1,000

Germline Mutation Analysis in Sporadic Breast Cancer Cases With Clinical Correlations
Ajaz, S., Zaidi, S.-E.-Z., Ali, S. M., Siddiqa, A., & Memon, M. A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.820610 · Cited by 8
Markov State Modeling Analysis Captures Changes in the Temperature-Sensitive N-Terminal and β-Turn Regions of the p53 DNA-Binding Domain
Koulgi, S., Achalere, A., Sonavane, U., & Joshi, R. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00380 · Cited by 7
Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
Arai, H., Minami, Y., Chi, S., Utsu, Y., Masuda, S., & Aotsuka, N. (2022) · Biomedicines · doi:10.3390/biomedicines10123008 · Cited by 7
Characterization on the oncogenic effect of the missense mutations of p53 via machine learning
Pan, Q., Portelli, S., Nguyen, T., & Ascher, D. B. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad428 · Cited by 7
Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers
Malhotra, L., Singh, A., Kaur, P., & Ethayathulla, A. S. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2435060 · Cited by 7
Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells
Kostrzewa‐Nowak, D., & Tarasiuk, J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.041 · Cited by 7
A Novel Dysfunctional p53 Mutation in the Human Neuroblastoma Cell Line TGW
Sugiyama, H., Arita, M., Min, Z., Zhong, X., Iwasaki, I., Hirano, K., Shimatake, H., & Hemmi, H. (2003) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.201.229 · Cited by 7
Involvement of human p53 in induced intrachromosomal recombination in Saccharomyces cerevisiae
Carratore, R. D. (2004) · Mutagenesis · doi:10.1093/mutage/geh038 · Cited by 8
Biology of Head and Neck Cancer
Chang, S., & Ha, P. K. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05283-2.00077-x · Cited by 7
Spherical and Worm‐Like Micelles from Fructose‐Functionalized Polyether Block Copolymers
Majdanski, T. C., Pretzel, D., Czaplewska, J. A., Vitz, J., Sungur, P., Höppener, S., Schubert, S., Schacher, F. H., Schubert, U. S., & Gottschaldt, M. (2018) · Macromolecular Bioscience · doi:10.1002/mabi.201700396 · Cited by 7
Targeted polyethylenimine/(p53 plasmid) nanocomplexes for potential antitumor applications
Zhong, Y., Wang, Y., Luo, L., Nurhidayah, D., Maruf, A., Gregersen, H. N., Wu, W., & Wang, G.-X. (2018) · Nanotechnology · doi:10.1088/1361-6528/aaf41a · Cited by 8
Single Nucleotide Variants Associated with Colorectal Cancer Among Iranian Patients: A Narrative Review
Jamshidi, M., Pour, S. M., & Mahmoudian‐Sani, M. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s248349 · Cited by 7
miR129‑1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non‑small cell lung cancer cells harboring a TP53 mutation
Yin, H., Xu, H., & Lin, Q. (2020) · Oncology Letters · doi:10.3892/ol.2020.11783 · Cited by 7
Databases and QSAR for Cancer Research
Malik, A., Singh, H., Andrabi, M., Husain, S. A., & Ahmad, S. (2006) · Cancer Informatics · doi:10.1177/117693510600200002 · Cited by 7
Translation of an STR-based biomarker into a clinically compatible SNP-based platform for loss of heterozygosity
Kissel, H. D., Galipeau, P. C., Li, X., & Reid, B. J. (2009) · Cancer Biomarkers · doi:10.3233/cbm-2009-0618 · Cited by 7
Clinical and molecular pathology of the metaplasia–dysplasia–carcinoma sequence in Barrett's oesophagus
Sanders, D. S. A., Tanière, P., Harrison, R. F., & Jankowski, J. A. (2003) · Current Diagnostic Pathology · doi:10.1016/s0968-6053(03)00033-4 · Cited by 7
Human germline and somatic cells have similar TP53 and Kirsten‐RAS gene single base mutation frequencies
Cole, D. N., Carlson, J. A., & Wilson, V. L. (2008) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20390 · Cited by 7
Evaluating Gene Set Enrichment Analysis via a Hybrid Data Model
Jianping Hua, A., Bittner, M. L., & Dougherty, E. R. (2014) · Cancer Informatics · doi:10.4137/cin.s13305 · Cited by 7
Constitutive and DNA Damage Inducible Activation of pig3 and MDM2 Genes by Tumor-Derived p53 Mutant C277Y
Pospı́šilová, Š., Siligan, C., Ban, J., Jug, G., & Kovar, H. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.296.2.5 · Cited by 7
Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment
Alimbetov, D. S., Umbayev, B. A., Tsoy, A., Бегимбетова, Д., Davis, T., Kipling, D., & Askarova, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11319-x · Cited by 6
Biallelic TP53 gain of function mutations in rapidly progressing solid tumors
Sande, C. M., Chang, B., Monga, V., Bossler, A., & Ma, D. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.02.001 · Cited by 6
Conformational Entropy as a Determinant of the Thermodynamic Stability of the p53 Core Domain
Bej, A., Rasquinha, J. A., & Mukherjee, S. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00740 · Cited by 6
The Biology of Thyroid Oncogenesis
Suh, I., & Kebebew, E. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0857-5_1 · Cited by 6
TP53 Mutations in Human Cancers: Selection versus Mutagenesis
Olivier, M., Petitjean, A., de Fromentel, C. C., & Hainaut, P. L. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_1 · Cited by 6
Carcinogenesis as the Sum of Its Parts
Wilson, V. L. (2012) · Disruptive Science and Technology · doi:10.1089/dst.2012.0021 · Cited by 6
Negative Regulation-Resistant p53 Variant Enhances Oncolytic Adenoviral Gene Therapy
Koo, T., Choi, I., Kim, M., Lee, J., Oh, E., Kim, J., & Yun, C. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.114 · Cited by 6
High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H
Imai, H., Kato, S., SAKAMOTO, Y., Kakudo, Y., Shimodaira, H., & Ishioka, C. (2013) · Oncology Reports · doi:10.3892/or.2013.2953 · Cited by 6
Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography
Özderya, A., Temizkan, Ş., Gul, A. E., Özuğur, Ş., Sargin, M. A., & Aydın, K. (2016) · Endocrine · doi:10.1007/s12020-016-1128-x · Cited by 6
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells
Nagai, Y., Mimura, N., Rizq, O., Isshiki, Y., Oshima, M., Rizk, M., Saraya, A., Koide, S., Nakajima‐Takagi, Y., Miyota, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81577-x · Cited by 6
The Cancer Research Database (CRDB): Integrated Platform to Gain Statistical Insight Into the Correlation Between Cancer and COVID-19
Ullah, S., Ullah, F., Rahman, W., Karras, D. A., Ullah, A., Ahmad, G., Ijaz, M., & Gao, T. (2022) · JMIR Cancer · doi:10.2196/35020 · Cited by 6
p53 Regulates a miRNA-Fructose Transporter Axis in Brown Adipose Tissue Under Fasting
Reinisch, I., Klymiuk, I., Michenthaler, H., Moyschewitz, E., Galhuber, M., Krstić, J., Domingo, M., Zhang, F., Karbiener, M., Vujić, N., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.913030 · Cited by 6
Characterization of Hydration Properties in Structural Ensembles of Biomolecules
Pradhan, M. R., Nguyen, M. N., Kannan, S., Fox, S. J., Kwoh, C. K., Lane, D. P., & Verma, C. S. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00453 · Cited by 6
The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.
Kloth, D. D., Iacovelli, L. M., Arbuckle, R. B., & McIntosh, A. C. (2010) · Europe PMC (PubMed Central) · Cited by 6
Evidence for an association of TP53 codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan
Dastjerdi, M. N., Salehi, M., Mohajeri, M. R., Morsali, F., Hamid, M., & Esfandiary, E. (2008) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 6
Understanding mutations and protein stability through tripeptides
Anishetty, S., Anishetty, R., & Pennathur, G. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.02.079 · Cited by 6
TAp63α indirectly regulates a cutaneous HPV promoter through complex formation with Jun family members
Fei, J.-W., Angel, P. E., Wei, Q.-X., & Villiers, E.-M. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209420 · Cited by 6
A naturally occurring p73 mutation in a p73‐p53 double‐mutant lung cancer cell line encodes p73α protein with a dominant‐negative function
Huqun, Endo, Y., Xin, H., Takahashi, M., Nukiwa, T., & Hagiwara, K. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01508.x · Cited by 6
Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53
Gorlov, I. P., Gorlova, O. Y., & Amos, C. I. (2005) · Human Mutation · doi:10.1002/humu.20242 · Cited by 6
A substantial proportion of microsatellite‐unstable colon tumors carry TP53 mutations while not showing chromosomal instability
Westra, J. L., Boven, L. G., van der Vlies, P., Faber, H., Sikkema‐Raddatz, B., Schaapveld, M., Dijkhuizen, T., Hollema, H., Buys, C. H. C. M., Plukker, J. T., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20148 · Cited by 6
Regulation of p53 DNA Binding
McKinney, K. M., & Prives, C. L. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_2 · Cited by 6
The European flounder (Platichthys flesus) TP53 functions as a temperature-sensitive transcription factor which inhibits cell growth in yeast
Cachot, J., Flaman, J., Frébourg, T., & Leboulenger, F. (2003) · Gene · doi:10.1016/j.gene.2003.09.052 · Cited by 6
Oncogenic R248W mutation induced conformational perturbation of the p53 core domain and the structural protection by proteomimetic amyloid inhibitor ADH-6
Liu, Q., Yu, Y., & Wei, G. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp02046d · Cited by 5
The multifunctional proline-rich domain of p53 tumor suppressor
Zhang, Y., & Dutta, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189326 · Cited by 6
Investigation of the impact of R273H and R273C mutations on the DNA binding domain of P53 protein through molecular dynamic simulation
Hephzibah Cathryn, R., & Doss, C. G. P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2283793 · Cited by 5
Role of artificial intelligence in cancer detection using protein p53: A Review
Patil, M. R., & Bihari, A. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10051-4 · Cited by 6
Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53
Taritsa, I. C., & Fossel, E. T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1529483 · Cited by 5
Multiple Malignancies in a Child with de novo TP53 Mutation
Woźniak, A. E., Fryer, A. E., Grimer, R. J., & Dowell, H. M. (2011) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2010.548439 · Cited by 5
Establishment and characterization of a lung cancer cell line, SMC-L001, from a lung adenocarcinoma
Choi, S., Lee, H., Choe, C., Shin, Y.-S., Lee, J., Moon, S., & Kim, J. (2014) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-014-9736-3 · Cited by 5
An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication
Smardova (1994) · Oncology Reports · doi:10.3892/or_00000073 · Cited by 5
Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes
Banerjee, S., Raman, K., & Ravindran, B. (2021) · Cancers · doi:10.3390/cancers13102366 · Cited by 5
POTENTIAL COUMARIN THIOSEMICARBAZONE HYBRIDS AS BRCA-1 MIMETICS FOR ER POSITIVE BREAST CANCER THERAPY: AN IN-SILICO APPROACH
Selvaraj, J. (2021) · Journal of medical pharmaceutical and allied sciences · doi:10.22270/jmpas.v10i4.1383 · Cited by 5
p53-Based Immunotherapy of Cancer
Leo, A. B. D. (2004) · KARGER eBooks · doi:10.1159/000082504 · Cited by 5
Databases and QSAR for cancer research.
Malik, A., Singh, H., Andrabi, M., Husain, S. A., & Ahmad, S. (2007) · PubMed Central · Cited by 5
Mouse models for generating P53 gene mutation spectra
Zielinski, B., Liu, Z., Hollstein, M. C., Hergenhahn, M., & Luo, J. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(02)00160-1 · Cited by 5
High-throughput detection of aberrant imprint methylation in the ovarian cancer by the bisulphite PCR-Luminex method
Hiura, H., Okae, H., Kobayash, H., Miyauchi, N., Sato, F., Satô, A., Suzuki, F., Nagase, S., Sugawara, J., Nakai, K., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-8 · Cited by 5
3DM from data to medicine
Joosten, H. (2007) · doi:10.18174/121924 · Cited by 5
Reply: Smoking and hepatoblastoma: confounding by birth weight?
Pang, D., & Birch, J. M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601144 · Cited by 5
Activating p53 Y220C with a Mutant-Specific Small MoleculePreprint
Zhu, X., Byun, W. S., Pieńkowska, D. E., Nguyen, K. T., Gerhartz, J., Geng, Q., Qiu, T., Zhong, J., Jiang, Z., Wang, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.23.619961 · Cited by 5
Systematic tracking of coordinated differential network motifs identifies novel disease-related genes by integrating multiple data
Shi, K., Gao, L., & Wang, B. (2016) · Neurocomputing · doi:10.1016/j.neucom.2015.12.120 · Cited by 4
Enhanced thermostability of Streptomyces mobaraensis transglutaminase via computation-aided site-directed mutations and structural analysis
Li, Y., Wu, B., Zhang, Y., Liu, L., Bai, L., & Shi, T. (2023) · New Journal of Chemistry · doi:10.1039/d3nj04708c · Cited by 4
Evaluating targeted therapies in older patients with TP53 -mutated AML
Sabile, J. M. G., Swords, R. T., & Tyner, J. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2344057 · Cited by 4
Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods
Wen, Y., Xu, P., Chen, Y., Meng, J., Zheng, M., Zhang, S., Teng, D., & Li, X. (2025) · Molecular Diversity · doi:10.1007/s11030-024-11095-1 · Cited by 4
Design, synthesis, and activity evaluation of indole derivatives as potential stabilizers for p53 Y220C
Li, L., Gu, X. S., Meng, J., Wen, Y., Yi, J., Xu, F., Zhang, L., Zhang, S., & Zuo, Z. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130161 · Cited by 4
Evaluation of Tumorigenic Risk of Tissue-Engineered Oral Mucosal Epithelial Cells by Using Combinational Examinations
Thepot, A., Morel, A., Justin, V., Desanlis, A., Thivillier, L., Hoffman, E., Till, M., Accardi, R., Tommasino, M., Breton, P., et al. (2010) · Cell Transplantation · doi:10.3727/096368910x515854 · Cited by 4
A Novel TP53 Germline Mutation in a Family with a History of Multiple Malignancies: Case Report and Review of the Literature
Agarwalla, P. K., Dunn, I. F., Turner, C. D., Ligon, K. L., Schneider, K. A., & Smith, E. R. (2008) · Pediatric Neurosurgery · doi:10.1159/000187125 · Cited by 4
Differential Regulation of Cutaneous Oncoprotein HPVE6 by wtp53, Mutant p53R248W and ΔNp63α is HPV Type Dependent
Fei, J.-W., & de Villiers, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035540 · Cited by 4
Incidental thyroid uptake on PET scanning: epidemiology, clinical significance, and management challenge
Corn, S. D., Mitmaker, E. J., Tabah, R. J., Ciarallo, A., & How, J. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.63 · Cited by 4
Nanomedicine Based Approaches to Cancer Diagonsis and Therapy
Roderick, A., Wettig, S. D., & Kaur, T. (2011) · InTech eBooks · doi:10.5772/18304 · Cited by 4
Prognostic role of PIK3CA and TP53 in human papillomavirus–negative oropharyngeal cancers
Resteghini, C., Perrone, F., Miceli, R., Bergamini, C., Alfieri, S., Orlandi, E. M., Guzzo, M., Granata, R., Galbiati, D., Cavalieri, S., et al. (2018) · Tumori Journal · doi:10.1177/0300891618765558 · Cited by 4
Type of TP53 mutation influences oncogenic potential and spectrum of associated K‐ras mutations in lung‐specific transgenic mice
Duan, W., Gao, L., Kalvala, A., Aguila, B., Brooks, C., Mo, X. M., Ding, H., Shilo, K., Otterson, G. A., & Villalona-Calero, M. A. (2019) · International Journal of Cancer · doi:10.1002/ijc.32279 · Cited by 4
Pharma-Oncogenomics in the Era of Personal Genomics: A Quick Guide to Online Resources and Tools
Joshi, R. P., Steiner, D. F., Konnick, E. Q., & Suarez, C. J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-24100-1_7 · Cited by 4
Evidence of Genetic Instability in Tumors and Normal Nearby Tissues
Geraci, G., D'Elia, I., del Gaudio, R., & Giaimo, R. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009343 · Cited by 4
Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary)
Lequin, D., Fizazi, K. S., Toujani, S., Souquère, S., Mathieu, M., Hainaut, P. L., Bernheim, A., Praz, F., & Busson, P. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-225 · Cited by 4
Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach
Cardellino, U., Ciribilli, Y., Andreotti, V., Modesto, P., Menichini, P., Fronza, G., Pellegrino, C., & Inga, A. (2007) · Mutagenesis · doi:10.1093/mutage/gem038 · Cited by 4
Molecular Biology of Bladder Cancer
Knowles, M. A. (2005) · Springer eBooks · doi:10.1007/1-84628-015-x_12 · Cited by 4
Extracting the Strongest Signals from Omics Data: Differentially Expressed Pathways and Beyond
Glazko, G. V., Rahmatallah, Y., Zybailov, B. L., & Emmert‐Streib, F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7027-8_7 · Cited by 4
'A variant of uncertain significance' and the proliferation of human disease gene databases
Nelson, D. R. (2005) · Human Genomics · doi:10.1186/1479-7364-2-1-70 · Cited by 4
P53, COX-2, iNOS Protein Expression Changes and Their Relationship with Anti-Oxidant Enzymes in Surgically and Multi-Modality Treated Esophageal Carcinoma Patients
Kaur, T., KHANDUJA, K. L., Kaushik, T., Kaushik, G., Gupta, R., Gupta, N., & Vaiphei, K. (2006) · Journal of Chemotherapy · doi:10.1179/joc.2006.18.1.74 · Cited by 4
Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance
Liu, S., Bishop, W. R., Dasmahapatra, B., & Wang, Y. (2004) · Drug Development Research · doi:10.1002/ddr.10362 · Cited by 4
The changes in the p53 protein across the animal kingdom pointing to its involvement in longevityPreprint
Bartas, M., Brázda, V., Volná, A., Červeň, J., Pečínka, P., & Zawacka‐Pankau, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.06.080200 · Cited by 4
Germline TP53 mutations and single nucleotide polymorphisms in children.
Valva, P., Becker, P. D., Streitemberger, P., Lombardi, G. M., Rey, G., Guzmán, C. A., & Preciado, M. V. (2009) · PubMed · Cited by 3
PITAR, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA
Jana, S., Mondal, M., Mahale, S. P., Gupta, B., Prasasvi, K. R., Kandasami, L., Jha, N., Chowdhury, A., Santosh, V., Kanduri, C., et al. (2023) · eLife · doi:10.7554/elife.88256 · Cited by 5
Pyrimidine Triones as Potential Activators of p53 Mutants
Fallatah, M. M. J., Demir, Ö., Law, F. V., Lauinger, L., Baronio, R., Hall, L., Bournique, E., Srivastava, A., Metzen, L. T., Norman, Z., et al. (2024) · Biomolecules · doi:10.3390/biom14080967 · Cited by 3
Mutant p53-Mediated Tumor Secretome: Bridging Tumor Cells and Stromal Cells
Qiu, L., Ma, Z., & Wu, X. (2024) · Genes · doi:10.3390/genes15121615 · Cited by 5
TP53 Codon 72 Heterozygosity May Promote MicrosatelliteInstability in Sporadic Colorectal Cancer
Dastjerdi, M. N., & Hamid, M. (2010) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 3
Defect in Ser46 Phosphorylation of p53 Protein : A Resistance Mechanism against p53 Gene Transfer in Oral Squamous Cell Carcinoma Cells
Ichwan, S. J. A., & Ikeda, M. (2008) · Journal of Oral Biosciences · doi:10.1016/s1349-0079(08)80023-0 · Cited by 3
Relative Stability of Wild-Type and Mutant p53 Core Domain: A Molecular Dynamic Study
Rohani, L., Morton, D. J., Wang, X., & Chaudhary, J. (2015) · Journal of Computational Biology · doi:10.1089/cmb.2015.0163 · Cited by 3
DysPIA: A Novel Dysregulated Pathway Identification Analysis Method
Wang, L., Xie, W., Li, K., Wang, Z., Li, X., Feng, W., & Li, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.647653 · Cited by 2
Antitumour Effects of Selected Pyridinium Salts on Sensitive Leukaemia HL60 Cells and Their Multidrug Resistant Topoisomerase II-Defective HL60/MX2 Counterparts
Tarasiuk, J., Kostrzewa‐Nowak, D., & Żwierełło, W. (2022) · Molecules · doi:10.3390/molecules27165138 · Cited by 3
Overexpression of SRD5A3 in Hepatocellular Carcinoma and Its Molecular Mechanism: A Study of Bioinformatics Exploration Analysis with Experimental Verification
Chen, E., Yi, J., Ren, Q., Mi, Y., Gan, Z., & Liu, J. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/7853168 · Cited by 3
KMU-191 Induces Apoptosis in Human Clear Cell Renal Cell Carcinoma Caki Cells Through Modulation of Bcl-xL, Mcl-1 (L), c-FLIP (L), and p53 Proteins
Kim, S., Kim, D., Kang, H., Hong, V. S., Jeon, J., Lee, J., Kim, K., & Park, J. (2023) · Journal of Cancer · doi:10.7150/jca.85650 · Cited by 3
Ant colony optimization for the identification of dysregulated gene subnetworks from expression data
Hanna, E. M., Hasbani, G. E., & Azar, D. (2024) · BMC Bioinformatics · doi:10.1186/s12859-024-05871-x · Cited by 6
Neuroblastoma: Role of MDM2 and SNP309 as Markers
Cattelani, S., Ferrari‐Amorotti, G., Soliera, A. R., Manzotti, G., Raschellà, G., & Calabretta, B. (2013) · Pediatric cancer · doi:10.1007/978-94-007-6591-7_3 · Cited by 3
Phylogenetic analysis of the p53 family
Pintus, S. S., Fomin, E. S., Иванисенко, В. А., & Kolchanov, N. A. (2006) · BIOPHYSICS · doi:10.1134/s0006350906040099 · Cited by 3
Features of missense/nonsense mutations in exonic splicing enhancer sequences from cancer-related human genes
Jin, P., Cai, R., Zhou, X., Li‐Ling, J., & Ma, F. (2012) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2012.10.001 · Cited by 3
Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells
Donninger, H., Binder, A. B., Böhm, L., & Parker, M. I. (2007) · Biological Chemistry · doi:10.1515/bc.2008.010 · Cited by 3
Adduction of Human p53 Gene by Fecal Water: An In vitro Biomarker of Mutagenesis in the Human Large Bowel
Greetham, H. L., Bingham, S. A., & Burns, P. A. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0642 · Cited by 3
Genetic Predisposition to Wilms Tumour
Scott, R. H., & Rahman, N. (2014) · Pediatric oncology · doi:10.1007/978-3-662-44003-2_2 · Cited by 4
Oncology over Internet: integrating data and analysis of oncology interest on the net by means of workflows
Milanesi, L., Scaglione, S., Porro, I., Merelli, E., Mauri, G., Marra, D., Fattore, M., Paoli, F. D., Bertolini, G., & Romano, P. D. (2005) · BOA (University of Milano-Bicocca) · Cited by 3
Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways
Kühnel, F., Zender, L., Wirth, T. C., Schulte, B., Trautwein, C., Manns, M. P., & Kubicka, S. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700632 · Cited by 3

Authors: Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P.
Affiliations: World Health Organization (CH)
German Cancer Research Center (DE)
National Institutes of Health (US)
Corresponding author: Hainaut, Pierre
ORCID: Olivier, Magali
Harris, Curtis C.
Hainaut, Pierre
Venue: Human Mutation
Publisher: Wiley
Published: 2002-05-03
Volume: 19
Issue: 6
Pages: 607-614
ISSN: 1059-7794 (ISSN-L)
1098-1004
DOI: 10.1002/humu.10081
OpenAlex: W2073576377
Cited by: 1,248
References: 14
Citations by year: 2026: 11 · 2025: 20 · 2024: 33 · 2023: 46 · 2022: 33 · 2021: 33 · 2020: 32 · 2019: 31 · 2018: 40 · 2017: 30 · 2016: 37 · 2015: 34 · 2014: 48 · 2013: 43 · 2012: 61
FWCI: 29.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4869 d)
Locations: Human Mutation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords: TP53 mutation, somatic mutations, TP53 polymorphisms, mutation patterns, cancer genomics, carcinogen exposure, viral infection, genetic background, database restructuring
MeSH terms: DNA Mutational Analysis, Humans, Mutation, Genes, Tumor Suppressor, Genes, p53, Li-Fraumeni Syndrome, Computational Biology, Internet, Databases, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The IARC TP53 database: New online mutation analysis and recommendations to users

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks